Novo Nordisk to Slash US List Prices for Ozempic, Wegovy
Newser • • business
Key Points:
- Novo Nordisk announced it will cut US list prices for its weight-loss drug Wegovy and diabetes drug Ozempic by up to 50%, reducing both to $675 per month starting January 1, 2027.
- The price reduction also applies to pill versions like Rybelsus and aims to help patients with high out-of-pocket costs, especially those with high-deductible insurance plans.
- This move intensifies competition with Eli Lilly in the growing GLP-1 drug market, which is projected to nearly double to $139 billion by 2030.
- Current cash prices for out-of-pocket consumers and discounts through federal programs like TrumpRx will remain unchanged.
- The price cut coincides with newly negotiated
